
Opinion|Videos|September 12, 2024
Comprehensive Analysis: Upa Outshines Dupi Across Key Measures
Dermatology experts analyze the superior outcomes of upadacitinib compared with dupilumab across key efficacy measures in atopic dermatitis treatment.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
2
Phase 2b Analysis Shows Consistent Vitiligo Repigmentation With Ritlecitinib
3
Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo
4
Dual ITK/JAK3 Inhibition Shows Strong Preclinical Activity in Severe Alopecia Areata
5








